Malignant giant cell tumor of soft parts
diseaseOn this page
Also known as giant cell fibrous histiocytomagiant cell malignant fibrous histiocytomamalignant giant cell neoplasm of soft partsmalignant giant cell tumor of soft parts (morphologic abnormality)malignant giant cell tumour of soft parts (morphologic abnormality)malignant Osteoclastomaundifferentiated pleomorphic sarcoma with osteoclast-like giant cells
Summary
Malignant giant cell tumor of soft parts (MONDO:0003561) is a cancer and 1 clinical trial. Top therapeutic interventions include nivolumab. A subtype of undifferentiated pleomorphic sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | malignant giant cell tumor of soft parts |
| Mondo ID | MONDO:0003561 |
| DOID | DOID:5638 |
| NCIT | C8380 |
| UMLS | C0334554 |
| MedGen | 90807 |
| GARD | 0023564 |
| Is cancer (heuristic) | yes |
Also known as: giant cell fibrous histiocytoma · giant cell malignant fibrous histiocytoma · malignant giant cell neoplasm of soft parts · malignant giant cell tumor of soft parts · malignant giant cell tumor of soft parts (morphologic abnormality) · malignant giant cell tumour of soft parts (morphologic abnormality) · malignant Osteoclastoma · undifferentiated pleomorphic sarcoma with osteoclast-like giant cells
Disease family
This is a subtype of undifferentiated pleomorphic sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › histiocytoma › undifferentiated pleomorphic sarcoma › malignant giant cell tumor of soft parts
Related subtypes (2): cutaneous undifferentiated pleomorphic sarcoma, undifferentiated pleomorphic sarcoma, inflammatory variant
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04420975 | PHASE1 | ACTIVE_NOT_RECRUITING | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NIVOLUMAB | 4 | 1 |
Related Atlas pages
- Drugs: Nivolumab